BeyondSpring Inc.
Moat Score — BeyondSpring Inc.
Total Moat Score
5 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 2 / 5 | BeyondSpring holds patents and regulatory designations (Breakthrough Therapy status in both the U.S. and China) around plinabulin, and its Phase 3 survival data and Lancet publication build scientific credibility, but it has no approved product or commercial brand yet, limiting realized intangible value. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a small clinical-stage biotech, BeyondSpring has no manufacturing or R&D cost-scale advantage over large pharmaceutical competitors; if anything it operates at a significant resource disadvantage. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | Plinabulin has not been priced or launched commercially anywhere; any future pricing power would depend entirely on regulatory approval, differentiated clinical data, and payer/reimbursement negotiations that remain unresolved. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Pharmaceutical products carry no network effect; a patient's or physician's use of plinabulin does not make it more valuable to other users. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Should plinabulin reach market, physicians and health systems could switch to established G-CSF-class alternatives or competing oncology regimens with relatively low friction, limiting durable lock-in even post-approval. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | The NSCLC and supportive-care oncology markets are large and attract many well-funded entrants (including BeyondSpring's own SEED partners Lilly and Eisai running competing internal programs), so there is little efficient-scale protection for a company of BeyondSpring's size. |